Cenobamate
ATC N03AX25 · 7 markets · 51 records
GB 12 records · 6 strengths
- 12.5 mgtabletOntozry 12.5mg/25mg tablets treatment initiation packOntozry 50mg tablets
- 200 mgtabletOntozry 50mg tablets
- 150 mgtabletOntozry 50mg tablets
- 100 mgtabletOntozry 50mg tablets
- 50 mgtabletOntozry 50mg tablets
- 25 mgtabletOntozry 50mg tablets
CA 11 records · 6 strengths
HK 9 records · 1 strengths
9 records · 0 manufacturers 9 registros · 0 fabricantes 9 个记录 · 0 个厂家 9 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
ES 7 records · 5 strengths
- 12.5 mgtabletONTOZRY ONTOZRY
- 200 mgtabletOntozry 50mg tablets
- 150 mgtabletOntozry 50mg tablets
- 100 mgtabletOntozry 50mg tablets
- 50 mgtabletOntozry 50mg tablets
US 6 records · 6 strengths
FR 5 records · 6 strengths
- 12.5 mgtabletONTOZRY 12,5 mg, comprimé + 25 mg, comprimé pelliculé
- 200 mgtabletONTOZRY 100 mg, comprimé pelliculé
- 150 mgtabletONTOZRY 100 mg, comprimé pelliculé
- 100 mgtabletONTOZRY 100 mg, comprimé pelliculé
- 50 mgtabletONTOZRY 100 mg, comprimé pelliculé
- 25 mgtabletONTOZRY 12,5 mg, comprimé + 25 mg, comprimé pelliculé
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
| Strength / form / release | US | GB | CA | ES | HK | EU | FR |
|---|---|---|---|---|---|---|---|
| 12.5 mg tablet | Xcopri | Ontozry 12.5mg/25mg tablets treatment initiation pack Ontozry 50mg tablets | Xcopri | ONTOZRY ONTOZRY | ONTOZRY 12,5 mg, comprimé + 25 mg, comprimé pelliculé | ||
| 200 mg tablet | Xcopri | Ontozry 50mg tablets | Xcopri | Ontozry 50mg tablets | ONTOZRY 100 mg, comprimé pelliculé | ||
| 150 mg tablet | Xcopri | Ontozry 50mg tablets | Xcopri | Ontozry 50mg tablets | ONTOZRY 100 mg, comprimé pelliculé | ||
| 100 mg tablet | Xcopri | Ontozry 50mg tablets | Xcopri | Ontozry 50mg tablets | ONTOZRY 100 mg, comprimé pelliculé | ||
| 50 mg tablet | Xcopri | Ontozry 50mg tablets | Xcopri | Ontozry 50mg tablets | ONTOZRY 100 mg, comprimé pelliculé | ||
| 25 mg tablet | Xcopri | Ontozry 50mg tablets | Xcopri | ONTOZRY 12,5 mg, comprimé + 25 mg, comprimé pelliculé | |||
unknown | Xcopri XCOPRI TABLETS 100MG AND 150MG (250MG DAILY DOSE MAINTENANCE PACK) XCOPRI TABLETS 12.5MG AND 25MG (TITRATION PACK) | Ontozry 50mg tablets |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
1 more strength/form rows are recorded only in HK · EU and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en HK · EU que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 HK · EU 有记录（未在本表显示）。 另有 1 個規格/劑型僅在 HK · EU 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.